SCHEMBL4508603

SCHEMBL4508603

CC[C@H](CNc1cc(C(=O)O)nc(-c2cc(Cl)ccc2O)n1)NC(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 2/20 0.39
▸ KDM4E B2RXH2 3/20 0.38
▸ CDK9 P50750 3/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ LMNA P02545 3/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ CASP3 P42574 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ SENP7 Q9BQF6 2/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ CDK5 Q00535 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ CDK5R1 Q15078 1/20 0.38
▸ SENP8 Q96LD8 1/20 0.38
▸ SENP6 Q9GZR1 1/20 0.38
▸ TRPA1 O75762 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.36
▸ MAPT P10636 3/20 0.36
▸ HPGD P15428 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3910866 1.00 SYK (0.39) SYKKDM4ECDK9SMN1; SMN2LMNA
SCHEMBL4508610 1.00 SYK (0.39) SYKKDM4ECDK9SMN1; SMN2LMNA
SCHEMBL3913700 0.80 LMNA (0.46) KDM4ECDK9SMN1; SMN2LMNANPC1
SCHEMBL3913706 0.80 LMNA (0.46) KDM4ECDK9SMN1; SMN2LMNANPC1
SCHEMBL3913704 0.80 LMNA (0.46) KDM4ECDK9SMN1; SMN2LMNANPC1
SCHEMBL4523758 0.79 SYK (0.39) SYKKDM4ECDK9SMN1; SMN2LMNA
SCHEMBL3978239 0.78 SYK (0.38) SYKKDM4ECDK9SMN1; SMN2LMNA
SCHEMBL3978233 0.78 SYK (0.38) SYKKDM4ECDK9SMN1; SMN2LMNA
SCHEMBL4514127 0.76 PRKD3 (0.43) SYKLMNAALDH1A1HPGDHSP90AA1
SCHEMBL4049100 0.76 AAK1 (0.43) SYKALDH1A1MAPTATMAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-10-01 — — US disclosed
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-10-01 — — US disclosed
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-10-01 — — US disclosed
WO-2007125331-A2 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247519-A1 AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE PKD2, PKD1, AADAT SYK 2554/4885KDM4E 757/4885CDK9 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback